Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

[Display omitted] •Chronic HCV prevalence and treatment rates among PWID vary widely across Europe.•HCV treatment scale-up is required in most sites to reduce HCV transmission.•Increasing OST/NSP coverage enhances HCV treatment prevention benefit. Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years. We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID. At baseline, chronic HCV prevalence varied from 55% (Finland/Sweden), and